{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:19Z","timestamp":1740107779530,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10147-021-02016-5","type":"journal-article","created":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T04:02:13Z","timestamp":1632024133000},"page":"2303-2309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan"],"prefix":"10.1007","volume":"26","author":[{"given":"Toru","family":"Matsugasumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Okihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Imura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-3210","authenticated-orcid":false,"given":"Osamu","family":"Ukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,19]]},"reference":[{"issue":"13","key":"2016_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa0810084","journal-title":"N Engl J Med"},{"issue":"8","key":"2016_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","volume":"11","author":"J Hugosson","year":"2010","unstructured":"Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725\u2013732. https:\/\/doi.org\/10.1016\/S1470-2045(10)70146-7","journal-title":"Lancet Oncol"},{"issue":"13","key":"2016_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310\u20131319. https:\/\/doi.org\/10.1056\/NEJMoa0810696","journal-title":"N Engl J Med"},{"issue":"6","key":"2016_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jjco\/hyp025","volume":"39","author":"C Hamashima","year":"2009","unstructured":"Hamashima C, Nakayama T, Sagawa M et al (2009) The Japanese guideline for prostate cancer screening. Jpn J Clin Oncol 39(6):339\u2013351. https:\/\/doi.org\/10.1093\/jjco\/hyp025","journal-title":"Jpn J Clin Oncol"},{"key":"2016_CR5","volume-title":"Screening guideline for prostate cancer: medical review","author":"Association JU","year":"2018","unstructured":"Association JU (2018) Screening guideline for prostate cancer: medical review, 1st edn. Association JU","edition":"1"},{"issue":"1","key":"2016_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00038-011-0266-4","volume":"57","author":"W Oberaigner","year":"2012","unstructured":"Oberaigner W, Siebert U, Horninger W et al (2012) Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 57(1):57\u201362. https:\/\/doi.org\/10.1007\/s00038-011-0266-4","journal-title":"Int J Public Health"},{"issue":"2","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1442-2042.2007.01957.x","volume":"15","author":"K Okihara","year":"2008","unstructured":"Okihara K, Kitamura K, Okada K et al (2008) Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int J Urol 15(2):156\u2013160. https:\/\/doi.org\/10.1111\/j.1442-2042.2007.01957.x (Discussion 161)","journal-title":"Int J Urol"},{"key":"2016_CR8","unstructured":"National institute of population and social security research. Population and social security in Japan 2019. http:\/\/www.ipss.go.jp\/s-info\/e\/pssj\/pssj2019.pdf. Accessed 20 May 2021"},{"issue":"4","key":"2016_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.juro.2015.04.075","volume":"194","author":"T Matsugasumi","year":"2015","unstructured":"Matsugasumi T, Baco E, Palmer S et al (2015) Prostate cancer volume estimation by combining magnetic resonance imaging and targeted biopsy proven cancer core length: correlation with cancer volume. J Urol 194(4):957\u2013965. https:\/\/doi.org\/10.1016\/j.juro.2015.04.075","journal-title":"J Urol"},{"issue":"4","key":"2016_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/PAS.0000000000000820","volume":"41","author":"JI Epstein","year":"2017","unstructured":"Epstein JI, Amin MB, Reuter VE et al (2017) Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 41(4):e1\u2013e7. https:\/\/doi.org\/10.1097\/PAS.0000000000000820","journal-title":"Am J Surg Pathol"},{"key":"2016_CR11","first-page":"170","volume-title":"TMN classification of malignant tumors","author":"International Union Against Cancer","year":"1997","unstructured":"International Union Against Cancer (1997) Urologic tumors: prostate. In: Sobin LH, Wittekind CH (eds) TMN classification of malignant tumors, 5th edn. Wiley, New York, pp 170\u2013173","edition":"5"},{"issue":"4","key":"2016_CR12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1. Screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618\u2013629. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"Eur Urol"},{"issue":"18","key":"2016_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S et al (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319(18):1914\u20131931. https:\/\/doi.org\/10.1001\/jama.2018.3712","journal-title":"JAMA"},{"issue":"2","key":"2016_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2019.04.033","volume":"76","author":"G Gandaglia","year":"2019","unstructured":"Gandaglia G, Albers P, Abrahamsson PA et al (2019) Structured population-based prostate-specific antigen screening for prostate cancer: the European association of urology position in 2019. Eur Urol 76(2):142\u2013150. https:\/\/doi.org\/10.1016\/j.eururo.2019.04.033","journal-title":"Eur Urol"},{"issue":"2","key":"2016_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA et al (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70(2):233\u2013245. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029","journal-title":"Eur Urol"},{"issue":"5","key":"2016_CR16","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.juro.2013.12.006","volume":"191","author":"F Cornud","year":"2014","unstructured":"Cornud F, Khoury G, Bouazza N et al (2014) Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 191(5):1272\u20131279. https:\/\/doi.org\/10.1016\/j.juro.2013.12.006","journal-title":"J Urol"},{"issue":"14","key":"2016_CR17","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-0044","volume":"20","author":"OF Donati","year":"2014","unstructured":"Donati OF, Afaq A, Vargas HA et al (2014) Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res 20(14):3705\u20133711. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0044","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2016_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.12954\/PI.12017","volume":"1","author":"Y Kitagawa","year":"2013","unstructured":"Kitagawa Y, Mizokami A, Namiki M (2013) Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. Prostate Int 1(2):65\u201368. https:\/\/doi.org\/10.12954\/PI.12017","journal-title":"Prostate Int"},{"issue":"11","key":"2016_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/pros.23997","volume":"80","author":"T Tabei","year":"2020","unstructured":"Tabei T, Taguri M, Sakai N et al (2020) Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. Prostate 80(11):824\u2013830. https:\/\/doi.org\/10.1002\/pros.23997","journal-title":"Prostate"},{"issue":"12","key":"2016_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1442-2042.2011.02895.x","volume":"18","author":"H Fujimoto","year":"2011","unstructured":"Fujimoto H, Nakanishi H, Miki T et al (2011) Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 18(12):876\u2013881. https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02895.x","journal-title":"Int J Urol"},{"issue":"9","key":"2016_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/iju.13380","volume":"24","author":"Y Kakehi","year":"2017","unstructured":"Kakehi Y, Sugimoto M, Taoka R et al (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 24(9):648\u2013666. https:\/\/doi.org\/10.1111\/iju.13380","journal-title":"Int J Urol"},{"issue":"9","key":"2016_CR22","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","volume":"15","author":"JP Droz","year":"2014","unstructured":"Droz JP, Aapro M, Balducci L et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404\u2013e414. https:\/\/doi.org\/10.1016\/S1470-2045(14)70018-X (PMID: 25079103)","journal-title":"Lancet Oncol"},{"issue":"3","key":"2016_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A et al (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69(3):500\u2013504. https:\/\/doi.org\/10.1016\/j.urology.2006.11.002","journal-title":"Urology"},{"issue":"10","key":"2016_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s10067-015-2943-9","volume":"34","author":"A Oliveira","year":"2015","unstructured":"Oliveira A, Vaz C (2015) The role of sarcopenia in the risk of osteoporotic hip fracture. Clin Rheumatol 34(10):1673\u20131680. https:\/\/doi.org\/10.1007\/s10067-015-2943-9","journal-title":"Clin Rheumatol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02016-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T02:03:39Z","timestamp":1636596219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,19]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02016-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2021,9,19]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}